Breaking News
Sort by:
Top Post
ProBioGen and ImmunOs Therapeutics Team Up to Deliver Innovative Therapy for Cancer Patients
ProBioGen, a Berlin-based specialist for developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, and […]
Amniotics Strengthens its Clinical and Regulatory Capabilities
Amniotics AB (publ) (Nasdaq Stockholm: AMNI), a developer of novel cell therapy products, has appointed […]
TFS HealthScience Appoints Eva Brike as Chief People Officer
TFS HealthScience, a global mid-size CRO, announced that Eva Brike has joined the company as […]
Dubai-Based Al-Futtaim Electronic - Techserve Partners with TytoCare to Expand Digital Health Services
TytoCare, the global health care industry’s first all-in-one modular device and examination platform for AI-powered, […]
Nym Health Names Or Peles Senior Vice President of Research & Development
Nym Health, a leader in autonomous medical coding, today announced that Or Peles has joined […]
EmpiRx Health Appoints Nada Nicholas as Senior Vice President of Business Development for Labor
EmpiRx Health, the industry’s only value-based pharmacy benefit manager (PBM), today announced it has appointed Nada […]
Seekyo Reinforces Scientific Advisory Board with Two New Members
Seekyo, a startup company specializing in developing smart chemotherapy drugs, today announces the appointment of two […]
NuvoAir Series A Funding Reaches $25M to Expand Patient-Centric Care and Clinical Trials Platform
NuvoAir, a leading digital healthcare company working in chronic disease management, raised $11M in a […]
Amniotics Secures Funding of SEK 4,8 Million from Vinnova to Develop Stem Cell Therapies
Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announced that it has received a non-diluting grant […]
Wandercraft Closes $45 Million Series C Financing to Accelerate Delivery of the World’s First Personal Self-Balanced Exoskeleton
Wandercraft, a leading healthtech company in dynamic robotics and exoskeleton technology, announced today a $45 million equity […]
Pneumagen Raises £3.8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)
Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more